Chronic post-surgical pain
Conditions
Interventions
Liposomal Bupivacaine Group:Local infiltration injection of Liposomal Bupivacaine (266mg, 20ml) at the median sternal incision and subcutaneous tissue by the surgeon after chest closure.
Control Group:Routine surgical chest closure and standard postoperative analgesic regimen, without local infiltration of drugs at the incision.
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 years or older; 2. American Society of Anesthesiologists (ASA) classification I-III; 3. Body mass index (BMI) 18-30 kg/m²; 4. Scheduled for elective median sternotomy cardiac surgery under general anesthesia; 5. Able to understand and willing to use tools such as the Visual Analog Scale (VAS) to report pain; 6. Mentally alert, able to understand and cooperate with relevant examinations.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women; 2. Severe respiratory dysfunction; 3. History of chronic pain; 4. Severe heart, liver, or kidney dysfunction; 5. History of alcohol or drug abuse; 6. Use of narcotic analgesics within 3 days before surgery; 7. Perioperative use of stress-dose corticosteroids; 8. Chronic non-cardiac pain; 9. Allergy to anesthetic drugs; 10. Recent history of radiotherapy or chemotherapy; 11. Mental or language disorders; 12. History of thyroid disease or epilepsy; 13. Major postoperative bleeding or receiving secondary treatment; 14. Emergency surgery; 15. Patients unable to provide informed consent; 16. Patients unable to complete pain assessment scales.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of chronic postsurgical pain (CPSP); | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative acute pain scores;Opioid consumption;Depression scores; | — |
Countries
China
Contacts
Public ContactQi Zeyou, Zhang Zhiyi
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed